Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Michael Steinhaus

Orthopaedic Surgery of the Spine Murray, UT Medical Doctor

NPI 1669866240 CMS profile 5705274

5911 S Fashion Blvd, Ste 200, Murray, UT 84107

Open in the dashboard

General payments

$129,925

176 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Steinhaus of Murray, UT is reported in the CMS Open Payments database as having received $129,925 across 176 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Orthopaedic Surgery of the Spine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $34,669 49
2024 General $47,408 41
2023 General $31,409 39
2022 General $14,212 25
2021 General $2,075 21
2020 General $151 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Steinhaus
  • Orthopaedic Surgery of the Spine median
  • Middle half of Orthopaedic Surgery of the Spine
  • National median

In program year 2025, general payments to Michael Steinhaus were reported at $34,669. Among 1,704 Orthopaedic Surgery of the Spine profiles paid that year, the median was $2,061 and the middle half received between $347 and $14,651.

Show as a table
Year Michael Steinhaus Orthopaedic Surgery of the Spine median Middle half National median
2019 $0 $2,106 $337–$18,608 $163
2020 $151 $1,213 $156–$15,082 $114
2021 $2,075 $1,834 $271–$15,617 $132
2022 $14,212 $2,015 $320–$17,036 $149
2023 $31,409 $1,925 $336–$14,599 $160
2024 $47,408 $2,110 $341–$12,483 $164
2025 $34,669 $2,061 $347–$14,651 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Globus Medical, Inc. $125,612 120 payments
  2. NuVasive, Inc. $1,156 12 payments
  3. Stryker Corporation $862 6 payments
  4. Medtronic, Inc. $786 13 payments
  5. SI-BONE, Inc. $210 2 payments
  6. Boston Scientific Corporation $190 4 payments
  7. NovApproach Spine, LLC $186 1 payment
  8. Intrinsic Therapeutics $169 1 payment
  9. Cerapedics, Inc. $134 2 payments
  10. Orthofix Medical, Inc. $117 1 payment
  11. Other $503 14 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Consulting Fee $83,571 28 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $27,275 7 payments
  3. Travel and Lodging $12,522 53 payments
  4. Food and Beverage $6,458 87 payments
  5. Education $99 1 payment
Products named General payments · program years 2020–2025
  1. QUARTEX $18,600 10 payments
  2. ExcelsiusGPS Robotic Navigation System Spine/Spine Surgery $17,504 8 payments
  3. EXCELSIUS GPS $11,650 20 payments
  4. ELSA $10,425 4 payments
  5. SABLE $10,207 5 payments
  6. ExcelsiusGPS Robotic Navigation System Robotics $9,564 12 payments
  7. Anthem $9,450 2 payments
  8. XLIF $9,375 13 payments
  9. CREO MIS Stabilization System $9,343 5 payments
  10. ALIF $3,500 1 payment
  11. Other $10,287 87 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

39

Median for Orthopedic Surgery: 203

Drug cost

$428

Median for Orthopedic Surgery: $1,433

Branded share of claims

0%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 13 $208
Methylprednisolone Generic 15 $118
Cyclobenzaprine Hcl Generic 11 $102

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$232,345

Medicare's payments for the services billed

Medicare patients

206

Average age 74

Services billed

865

114 women, 92 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 67%
Depression 32%
Ischemic heart disease 30%
Chronic kidney disease 27%
Diabetes 25%
Osteoporosis 20%
Heart failure 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

176 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery of the Spine in Utah

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record